July 08, 2026 08:49 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Dalal Street bleeds! Sensex tanks over 1,600 points after Trump declares Iran ceasefire 'over' | 'It's over': Trump says on ceasefire with Iran | PM Modi visits 1,000-year-old Prambanan Temple in Indonesia, shares majestic aerial view of the holy site | Baruipur minor rape-murder case: Key accused Pravash Mondal killed in encounter | 'We have been cheated': Egypt coach slams refereeing after Argentina match sparks controversy | From 0-2 to victory! Argentina stage miraculous comeback amid referee drama to crush Egypt's World Cup dream | Amid outrage over Baruipur, another minor girl allegedly raped in West Bengal | Kerala rain fury: 2 dead, 10 feared trapped as massive Wayanad landslide triggers rescue race | Rick Scott revives Bin Laden issue, questions Pakistan's credibility as Iran mediator | Mbappé vs Paraguayan Senator: Ugly World Cup spat spirals into international controversy
Image credit: UNI

CCI green lights Nirma Ltd's acquisition of Glenmark Life Sciences

| @indiablooms | Dec 20, 2023, at 05:07 am

New Delhi: The Competition Commission of India (CCI) on Tuesday gave its nod to Nirma Limited to acquire the majority shares of Glenmark Life Sciences Limited.

Nirma Limited plans to acquire these shares by purchasing them from Glenmark Life Sciences' promoter and from public shareholders through an open offer, the antitrust watchdog said in a statement.

Nirma Limited has a diverse presence and operations in India and the USA, involved in various products such as soda ash, soaps, detergents, salt, caustic soda, Linear Alkyl Benzene, and other industrial items.

On the other hand, Glenmark Life Sciences is primarily involved in the development, manufacturing, and sale of Active Pharmaceutical Ingredients (APIs) and intermediaries.

It also provides contract development and manufacturing organization (CDMO) services for APIs.

The company's portfolio includes over 130 APIs catering to chronic therapeutic segments like cardiovascular disease, central nervous system disorders, pain management, and anti-diabetics.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm